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Amendment  to  the proposat for  a 
COUNCIL  DIRECTIVE,. 
on  the wholesale  distri-bution  ·'•·.:>  ..  - . 
of medicln·al·products: ·for··human  use  .. :  :- · :: ...........  _  .......... 1: .:.  ~--':< 
.,_-- -- ·  ~- :  :-·  -- -~t ?1 ts _pleria:.t:Y 'session-on-·.12 ·June ~1991-~tbe  :European  ~Parliament  -·~~ov.ei  ,'the- ·  -~  ,  ~- ._--
..  .  .  '  . 
-'  ..  .  '~  COimnissien·~.prqposaJ. on the :wholesa.:Le-/distribu:t.ton<of·:me:;licina.l ·:produ,cts.for:  ..  :" ·  '>': _.  .  .-
human use {OOM(89)607 :fina.l;  SYN.-229 ;of 26 J~  :r990}.  .  .  ...  , 
-- 'Pursua.rtt to:Art.i:CJ.e-149(3) -of·  the~E:re Treaty, .the 'Conmiission-'"l:lBs decided to  •  , 
.make  11  mnerxllne:rits  to its  ,prqposa.l. 
First, the Commission has incl'l.ldEd -Parliament's ame:riiments -concerning the 
' ·  .- -,public serv:Lce 'obligations of :  wholesaJ.ers suppl  yi.I)g  · pb.a.rma.cies ·--: ,  ·Since not 
·  :aJ.J.  the Member States ·apply this system, it was  founi inappropriate to 
·introduce it·· thr~t  the Community.  On the other·  ha.tii,  the  :new  rules 
must allow the Member  States which practise this system ·to retain .it  . 
. .  Many of the amendments  adopte:l  .. by Parlia.rnent are designed to  .. t:i,g'hten up the 
dbligations 1mpose1.  on all wholesale distributors of maticinaJ. .products  . 
.  The Commission feels that these .abllgations. come  un:ier the gu1d.e1ines on 
.  good distribution practices.  The COnunission has acceptei Parliament's 
amend.ment  caJ 1 1 ng  for these guidelines to be pubJ.1sh.ed  w1 thin two  years of 
adoption of -the Directive a.n::l  the amemment requiring all wholesaJ.e 
distributors of me:licinaJ. products to give an underta.king to cornpl  y  with 
them. 
The Coimllission has not acceptei the amendments  stipulating that all 
wholesaJ.e distributors of medicinaJ. :products must have a  pharrna.cist at 
their disposal..  This requirement ·.would  have posEd _serious problems in at 
.least half the Member  States ani cannot be  justifiEd. on public health 
·groun:Js. -.:)-
Amendment  to the  proposal  for  a 
COUNCIL  DIRECTIVE 
on  the .. wholesale dlstributic:1  SYN  229 
of medicinal  products  for  human  use 
(Presented  by  the  Commission  In  accordance  with 
Article  149  paragraph  3  of  the  EEC  Treaty) 
Original  proposal  Amended  proposal 
Titel  and  visas unchanged 
First  recital  unchanged 
First recital  a  (new) 
Whereas,  according  to  Article  lOOa, 
the  completio'n  of  the  internal 
~arket  must  b~~based  on  the  highest 
p_ossible  level  of  environmental, 
p u b 1 i  c  h e a i"t h  a n d  c o n s u me r 
protection; 
Second  recital 
Wherea~  .the  wholesale  distribution 
of  medi~inal  products  for  human  use 
is  at  present  subject  to  different 
provisions  in  the  various  Member 
States;  whereas  many  operations 
involving  the wholesale  distribution 
of  medicinal  products  ~  cover 
simultaneously  several  Member 
States; 
Whereas  the  ~holesale  djstribution 
of  medicinal  products  for  human  use 
is  at  present  subject  to  different 
provisions  in  the  various  Member 
States;  whereas  many  OP,erat ions 
involving  the  whol~sale distribution 
of medicinal  products  cover  and  will 
increasingly  cover  simultaneously 
severil  Member  States; 
Third  recital  unchanged 
Fourth  recital 
Whereas  any  person  involved  in  the 
wholesale  distribution  of  medicinal 
products  should  be  in  possession  of 
a  special  authorization;  whereas 
f:l_b__?,·rmacists  and  persons  authorized 
to  suoply  medicinal  products 
directly  to  the  public,  and  who 
cor.fi_~  themselves  to  this  activity, 
~.hou I ~·U2  ..  ~.-~ernp!_  _t:_~~m_<_)_bta  )~.:!_n_g_ th  1  ~­
.J.U_~~q_ri_z.at1on;  whereas. i~  _l_s  __  !_lw_ay~ 
Pecessary  _In  order  to  control  the 
~ompj~~~--- ~~...!-~.-·<?_f._ -~-i-~_-lr·i_Q~i_  i~-n ~~-f 
medicinal  products.  that  pharmacists 
and~1·sons  auth.orized  to  deliver 
medicinal  products  to  the  public 
ke_~  records  sho~  entry 
L_~ a  11  ~-~ c _l1  ..  9..r:!.~ _; 
Whereas  any  person  involved  in  the 
wholesale  distribution  of  medicinal 
products  should  be  in  possession  of 
a  specific  authorization;  whereas 
the  definition  of  distribution  does 
not  cover dividing  up,  packaging  and 
presentation  operations  refErred  -~-
1 n  Article  16  of  Di r:ect i v~  _ __7_5_DI_9 
~r:!d  __  J.r~-~h~  .... 3_m~f1(jmen t s  the rc to  or 
oper::at_1~_!l~  ___ l_1_~~ed  ln  dir·ecl  ·.upply 
l~- ~he. p_~:~~l_lc; ..  _'Ortg·Fnal·  proposal 
·-4-
:Amemded  _,pr.ooosaJ ... 
·Fourth  reC'i tal  a  (new) 
Whereas  it  is  ·nece-ssary  to  lay  down 
uniform  rules  applicable  throughou.t 
the  Community  with  a  v·i ew  l<? 
establishing  the  ·conditions  ·for 
o b  t  a  1 n  1 n g  a  u  t  h ·o. r  1. z a l  i  o  ~1'1.  , 
arrangements  ·1n·  connection  wHh 
transpor.t,  personnel  and· premi·ses, 
and  the  procedures  for ,the  checks  to 
be  carried out  by· the Member  St·ate·s.; 
Fifth recital  unchanged 
Art i c l:e  1  paragraph ·1  and  2 unchanged 
Article  1(2a)(new) 
2a.  For  th·e  purpose.s  of  thi.s 
d  i ·r  ·e c t  i  v e  '  p u b 1 .i  c  ·.s  e r  v i  c ·e 
--obl i-qa.tions'  shall  inc.lude  the 
=.o.=b:...l:...1.:..'  ;zg..::a:...:t::..i.:...o:::.:.:n~__:.f..:o:...:r~_.;w:.:..:..:h..::·o:...:l:...:e::..::.s..::a:...:l:...:e:.;.r~s-~to 
guarantee  a  constant  -r.ange  ·of 
medicjnal  products  to meet  th.e  nee.ds 
·of  a  geographically  .determined 
.terri tory  and  to  en sure  the  .s·upp 1 y 
at  very  short  not·i.ce  o·f  the  products 
r.e·ques.ted  throughou.t  the  .te·rri tor.y_ 
.!.!} _  _g~  ~  n_~.Q!l_._ 
Articles  2,  3  and~-unchanged • 
Am::J::::,,.,  ;:,·,-C';•osal 
--~-- -~ 
Article 5  (a)  and  (b)  unchangeo 
Article 5  (c) 
(c)  they  must  undertake  to  ful fi 1 
the  obligations  incumbent  on 
them  under  the  terms  of 
Article 6. 
(c)  they  must  undertake  to  comelt 
with  sou~d  distribution 
practices  and  to  establish  that 
they  have  the  requisite means  at 
their .disposal  to  apply  them  in 
practice. 
Article 6  (a)  unchanged 
Art I  e I  e  6  (b) . 
(b)  to  obtain  medicinal  products 
only  from  ... persons  who  are 
themselves  in  possession  of .the 
authoriiation  ~eferred.  to  in 
Article  3(1)  or  who  ~re exempt 
from  obtalnln9  this 
aulhorfzalfon  undt!r  the  terms 
of Article  3(2); 
(b)  to  obtain  medicinal  products 
only  from  persons  who  hold  an 
authorization  as  referred  to  in 
Article  16  et  se.9 .. .2.~  __ _g_~:.ec~i~~ 
.?.if.l.L~  /.E. ~ C ,  o r·  ..  w h o  a r e 
:.  themselves  fn•:  posses:; ion  of  lh(! 
author! zal t·on  referred  lo  in 
Article  3(1)  or  who·  are  e..<empl 
from  obtaining  this 
authorization  under  the  terms 
of Article  3(2); 
Article 6  (c)  unchanged 
Article 6  (d) 
(d)  to h.!:!!_  an  emergency  plan  which  (d)  to  accept  an  emergency  plan 
allows  participation  in  any  which  allows  participation  in 
action .of  withdrawal  from: the  any  action  of  ·wi thdrawa 1  from 
market  ordered  by  the  competent.  the  market  ordered  by  the 
author-ities  or  tnH iated  by  the  competent  authorities  of  the 
manu fac ture.r.  of  the  medicinal  ·.~  Member  State or  initi.ated  by  the 
product  co~cerned;  manufacturer/importer  of  the 
.·.:.  medicinal  product· concerned: 
Article 6  (e),  (f) and  (g)  unchanged 
.  ·.··".  ~ -6-
Or i.g ina J  proposa t  Amended  proposal 
Arti.cle  7 
With  rqprd. to  the  supply  of  medicinal  products  to 
phannacisu and  persons  authorized  to supply  medicinat. 
pr~duc:u  ro rhe publiC  .. Member  States shaH not im~  upon. 
rhe holder of an authoriZation re!crrcd to in Article J: {1 ), 
which  has  beer.  granted by another  Member  State,.  any 
obligation strict·!l' than those.rhey impose on persons which 
they· have  themselves  authorized  to carry out equivalent .  .  ......:.....:..:-
Th!  publtc.  servic~  obligations 
tmpose.d  by  certaiA Kember  State-s  on 
wholesalers  establtsh~d  .  .  .  ln  the1r 
terrltortes  shall  not  be affected  b 
thts directtve.  ....£Y. 
Articles 8  and  9  unchanged 
Article  10 
If appropriate,  the  Commission  shall 
publish  guidelines  on  good 
distribution  practices.  In  that 
~  the  pharmaceutical  committee 
instituted  by  Co u n c·i 1 
Decision  75/320/EEC1  shall  be 
consulted. 
Within  a  period  of  two  years  from 
the  date  of  adoption  of  this 
directive,  the  Commission  shall 
publish  guidelines  on  good 
distribution  practices.  It  shall 
update  this  publication  annually. 
It  sha  11  consu  1 t  for  this  purpose 
the  pharmaceutical  committee 
instituted  by  Council  Decision 
75/320/EEC. 
Art i c I es  11  ·and  12  unchanged 
• 
1-• 
Amendment  to  the  proposal  for  a 
COUNCIL  DIRECTIVE 
on  the  legal  status  for  the supply 
of medicinal  products  for  human  use -- --·········-··-··-····-··· --·-------.-··---···- ·---··- -··.···  .....  - -·--····-- ----·····--·  -------------·---- --- ·····- -···-
At its plenary session on 12 c1'uDe  1991  tbe European Parliament approved the 
Coimnission proposal. conoern1.ng the legal. status for the supply of meiicinal 
prcxiucts for human use (OOM(89)607  f1na.l,  SYN  230 of 26 January 1930).  ·~ 
Pursuant to Article 149(3) of the ~Treaty, the Commission has decided. to 
make  13 amen::Une.nts  to its proposal.. 
In its opinion,  Parliament proposei a  system for the classification of 
meiic1na.l prcxiucts very different to the system envisagei by the 
Ccmunission.  The COrcunission has decid.ei to accept Parliarnent's suggestion 
a.m.  has therefore includei aJ.l the amen:irnents  concern.ing the classification· 
system.  The title of the proposal for a  Directive has also been a.menie::l, 
as requestei by Parliament.  As a  result,  the suggestei a.merrlments  to 
Article 4  of the Commission '.s  origi.na.l proposal are no  longer necessary 
since the classifica.  tion criteria are now  includei in Article 3  of the 
arnen:ied  proposal. 
The Commission has also acceptei Parliament's arneniments allowing a  time 
•·  . 
lirni  t  of five years from  the date of adoption of the Directive· to draw up a 
~list of the meiic1na.l prcxiucts .ava1lahle without meiical. prescription ani. a 
.  '  . 
. list Of  prcxitJCts  availal:>le .On  meiical pre$Qription. Onl¥.  . 
·' 
i  . • 
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Amendment  to  the  proposal  for  a 
COUNCIL  DIRECTIVE 
SYN  230 
on  the  legal  status  for  supply 
of medicinal  products  for  human·use 
(Presented by  the Conunission  In  accordance  wi.th 
Article  149  paragraph .3  of  the  EEC  Treaty) 
Original  proposal 
Titel 
Pioposal  for·  a  Council  diiecti~e 
concerning  the  legal  status for  the 
supply  of'  medicinal  products  for· 
human  use. 
Amended  proposal 
Proposal  for  a·  Council  directive 
concerning· ·the  legal  status  for  the 
~upply  of  medicinal  products  for 
human  use  and  their classification. 
Visas  and  three  first  recitals  un~hanged 
Fourth  recital 
Whereas,  moreover,  .persons  moving 
around  within  the  Community  have  the 
right  to  carry  a  reasonable quantity 
of  medicinal  products  legitimately 
obtained  for  their  personal  use; 
whereas  it must  also be  possible for 
a  person  established  in  one  Member 
State to receive  from  another  Member 
State  a  reasonable  quantity  of 
medicinal  products  intended  for  his 
personal  use;  whereas  it  is 
important  therefore  to  harmonize  the 
QQnditions  of  delivery  of  medicjnal 
products  to  the  public; 
Whereas,  QOreover,  persons  moving 
around  ,  .. .-ithin  the  Commw1ity  have  the 
right  to  carry  a  reasonable quantity 
of  medicinal"  products  legitimately 
obtained  for  their  personal  use; 
whereas  it must  also be  possible  for 
a  person  established  in  one  Member 
State to  receive  from  another  Member 
State  a  reasonable  quantity  of 
medicinal  pr?Oucts  intended  for  his 
personal  usej:, 
Fifth  and  sixth  recitals unchanged ··.! . -
-4-
·  . -,Qr:ig·ina·l.-proposa L_  .....  - ...  1  -:  ....  .  ...  ·.Amended  p.r.oposa ;:._ 
.  r.;. ~- :  ;-~¥ ':.;  ~  .•  ~  '  '  --. _  .. - ... ,._ .  ~  -·- .  .  ....  ,.,... 
Artie  le  1 
... .;,1..  This  D.irec;:tive··concerns  .the 
..  , legal  status  .for . the  ·supply  of 
..  medicinal  product:s. ,for. human. use. in 
. :the community: 
2.  For  the  purpose  of  this  Council 
Dir:ective,  .the  d-efinition  of 
·'medicinal  product'.  in Article . 1  of 
Council . -Directive  65/65/EEC  shall 
apply. 
.· 
.1  •. :.  · Th-i·s:·.oi.tective  concerns· ·:the  :.· 
·legal·  sta:t.us ·for  ..  ·the ::supply  o.f 
· medicinaL products  for· human  use·. and 
their  classification  in  ttie 
-Community  as: 
-·medicinal  products subject  to 
.medical ·prescription, 
- medicinal  products  not  subiect 
to medica-l  prescription. 
2.  For· the  purpose· of  this  Council 
. Direc:tive,  the  definitio-n  of·. 
'medicinal  product'  s·et . out ... in 
.Article  '1,  .of  Co.uncil  ·oirect.i:ve. 
65/65/EEC shall apply. 
_In  addition, 
'·medical  prescription'  shall 
mean:  any  prescript.ion.  emanatcing 
.from  a  professional  guali fied'  to 
prescribe medicinal  products. 
.. 
•  I '  ,· 
'•. 
o~lglnal  proposal 
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Amended  proposal 
Article  2 
1.  When  a  marketing authorization is 
9ranted,  the  competent  authority 
shall  specify  the  classification 
of  the medicinal  product: 
medicinal  product  subject  to 
medical  prescription  .. 
medicinal  product  not  subject  to 
medical  prescription. 
To  this  end  the  criteria  laid  down 
in Arficle  3<1>  shall  apply. 
2.  The  competent  authorities  shall 
specify  the  subcategories  .of 
medicinal  products which  can only 
be  supplied  on  medical 
prescription:  ·In  this  case  they 
shall  use  ...  the  following 
classification: 
(a)medicinal  products  available  on 
renewable  or. non-renewable 
medical  orescripti6n, 
(b)medicinal  products  subject  to 
special  medical· prescription. 
(c)medicinal  products  available  on 
restricted  medical  prescription 
reserved  for  ·certain  soecialized 
~-
)2 0,,  tq_!·na 1.  pr:.oposa·l . 
-· 
Article  3 
1.  Whi:il · :a  marketing  :authorization  is  granted,  the· 
competeiu·· :nuhurity.  ~hall' specify  the legal  status for  the . 
supply of the .1ncdicinal  product:  ·  . 
m~dicinal product nofsubject to medical prescription, 
-.  medicin~l  product  subject  to  medical  pr~scription, 
mentioning  nne . of  the · categories  referred.  to  in 
Article 2. 
To  this  end,  chc  criteria  laid  down  m  ArtiCle 4  shall 
apply. 
2.  A11  medical  products  containing a. 
·new  chemical  shall  be  ·subject  to 
·medical  prescription.  ahd  classed 
in  one  of  the categories  referred  to 
in Article  2. 
Amended  proposaJ .... ,.  .... 
... 
1.Hedi?ina1 products hall· be'Subject· 
to· meshcal- prescription  :where.:  ·  · . 
they · present · a  danger: · directly 
or  indirectly.  even  under  normal 
conditions  of  use  if  taken 
without  medical  suoervision· or· 
they are used  frequently  and  to a 
yery  large extent  under  the wrong 
conditions  and  this  is  likely  to 
cause· a  direct or  indirect danger 
to health or 
they  contain  substances·  or 
preparations·  based  on  substances 
whose  eff~cts and/or side effects 
require· more detailed research or. 
they  are,  w~th  cert~irr exceptions 
administered  parenteral l.y  or  ' 
they  a· r  e· 
parenterally 
they  cause 
dependence. 
a d  m i.  n  i  s  t  e  r· e d' 
or· 
addict ion  and /or 
2.  Where  Member  States  specify  a 
subcategory  of  medicinal  product 
subject  to  special  medical 
prescription.  account  shall  be  taken 
of  the  following  elements.:  . 
the  presence  in·  the  medici na 1 
product  of  a  non-exempted.  dosage. 
of  a  substance  classified:  as  a 
p s y c h o t  r o p i c  o r  a  n a r c o. t  i c 
substance  within  the  meaninc  of 
the  relevant  interna-tional· 
conven.tions  (United  Na-tions 
Conventions  of  19~1  and  1971)  or 
the  poss·ibil'itv  that  the 
medicinal  product  could.  if' 
improperly·  used.  give  r.ise  to·. 
major  risks  of  medicinal  abcse. 
cause addiction or  be  misused for 
il1~ga1 purposes.or 
·-.\  .,  ., 
~4 
~' 
!!  .. 
.,  -~·--··· -. 
.  ~.:.:: 
,'.:  'J 
3.  The  competent  authority  shall 
publish  at  least  annually  the  list 
of  medicinal  products  subject  to 
medical  prescription,  specifying  the 
category of classification. 
.-7-
. ' 
..  -~,,:~en~.e~  propos a  I 
tbe  presence  in  thP  medicinal 
produCt  of  a  substance  which. 
because  of  its  novelty  or 
properties.  could  be  included  in 
that  category  as  a  precautionary 
'measure. 
2a.  In  cases  where  Me!!lber  States 
sOOcify  a  subcategory  of  medicinal 
products  subject  to  limited  medical 
prescription.  they  shall  take 
account  of  the  following  elements 
medicinal  products  which.  by 
reason  of  their  pharmacological 
characteristics  or  their  novelty 
or  in  the  interest  of  public 
health,  are  reserv('d  for  use  in 
treatments  which  can  only  be 
carried out  in hospitals. 
·medicinal  products  employed  in 
the  treatment  of  illnesses  which 
require  diagnosis  in  a  hospital 
or  other  institution  \o:ith 
adecuate  facilities  for 
diacno:sis,  but  where 
administration  and  follow-up  can 
be  carried  out  outside  the 
hospital  or  in  establishme:-,ts 
eguipo-~d  ~o.·i th  adecuate diagnostic 
facilities. 
r.~edic:nal  or·oducts  for  use  by 
out-pati<:>:1ts  which  could  proeuce 
.severe- adve~se effects  and  which 
there~c:'e  call  :'or  supervised 
treatr.:e:1:. 
3.  The  compe~ent  authority  shall 
publish  at  least  annualiy  the  list 
of  medici:1al  products  subject  tc 
medical  prescription  specifying  the 
category  of  classification  ar:d 
circulate  this  list  to  the  medical 
professiona!s  in their territory. ·or'iQtnat·:proposal < 
l.  Medicinal products :WhiCh •Contain :substances ·wniCb-
are likdy ro .present a .di~ea .or.!indirea ;danger to :human · 
Amende:d- ;J)·r-~posa  :J. 
_llh.e  ll:ega!l  .sta,tus ·o:f.  ~u_ppif·y  of 
:a  !med•i-cJna I  ,pr.oduc:t  ·sha 1 1·  be 
-health, cven-under--normal·conditionscof  euse.~sh21l·not :be---·· ·  ......  - -·  --
supplied to the public .without :medical.prescription. -Jl'hc  :set cu.t  :l.n  ·the .mar
1ke:t il.ng 
.following criteria shall :be .taken into -consideration iin •th'is  :aut.ho.r 1 z·at :lon  and J:ncl uded 
1 n 
.respect: 
(a)  p01c:ntial  risks  appearing  during ·the  _preclinical  and 
clinical rests and trials; 
(b)  ~o-vel·~- of  t~e.  acti~e ;principle, as stared ·in  AnicleJ_, 
r·-- o--ph2, 
(c)  possibility of serious side effects in .normal conditions of 
use; 
(d) .serious  risks  associated  with  contra-indications  .and 
precautions for use; 
(c)  indications  requiring  a  medical  diagnosis  or  special 
medical supervision; 
:ii  harmfulness of constituents under normal conditions of 
use, taking imo accounr posology, pack size or possible 
excessively extendl·d treatment; 
(g) ·parenteral administration, e.xcept when very ·long term 
.illness requin.·s ail  aCTi"e  panicipation 'by the p:nient  in 
the tre:nmcnt (for example: di.1betes); 
(h)  important risk of abuse, :lddiction or misuse for criminal 
purposes, 
2.  ·Morco•·cr, mcdic:ll·product~ which •may  be  avaii:Jblc 
without prescription sh;tll show a substami:1l safety in usc in 
:the  trearinenr  of  minor  ::~ilmcm's  or  symptoms;  usually 
capable of .rapid. and spontaneou-s relief, which  are .easily 
identifiable  by  users  :tnd  do ... not  justify.  a  medical 
consulr:nion.  ..! 
'  /' 
the  summa·ry  of  .the  pr.oduct 
_character~stlcs. 
•  I"" 
/  :'). 
.; 
,. 
J"  .  -/I.J .. 
.. 
·. 
j 
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Original  proposal 
Article  5 
1.  Within  two ye:us  of adoption of this  Directive, the 
·Member States shall communicate to the Commission and to 
the other Member States, the  fist  of medicines  which  are 
available only  on  medical  prescription  on  their  territory, 
mentioning the category of classification. 
2.  Each  year  Member  States  shall 
communicate  to the Commission.and  to 
the  other  Member  States  the  changes 
that  have  been  made  to  the  list 
referred  to  in paragraph  1. 
3.  Within  four  years of adoption  of 
this  Directive,  the  Commission  shall 
submit  a  report  to  the  Counc~ 
the  application  of  this  Directive. 
This  report  will  be  accompanied,  if 
necessary,  by  appropriate  proposals. 
1.  Unchanged 
2.  Each  year  Member  States  sha  11 
communicate  to  the  Commission  and  to 
the  other  Member  States  the  list 
referred  to  in  paragraph  1  and  the 
changes  that have  been  made  thereto. 
3.  Within  five  years of  adoption  of 
this Directive,  the  Commission  shall 
draw  up  a  1 ist  of  the  medicinal. 
products  in  all  Member  States  which 
are  available  only  on  medical 
prescription.  The  list  shall  apply 
to all  Member  States. 
Within  five  years  of  adoption 
of  this  Directive,  the  Commission 
shall  draw  up  a  list  of  the 
medicinal  products  in all  the  Member 
States. which  are  available  without 
medical  prescription.  'This  list 
shall  apply  to  all  the  Hember 
Articles 6  and  7  unchanged :': 
'.  ..  ..,; 
Amendment  to  the  proposal  for  a 
COUNCIL  DIRECTIVE 
on  the  labelling of medicinal  products  for  human  use 
and  on  package  leaflets 
-'• 
,,.  . 
-. 
"  ' . -2-
At its plenary. session on 12 JUne 1991  the European Parliament. approvei the 
Commission proposal on the labell.ing of me::licinal,products for human.use 
.. ·ani on package leaflets (cx::lM(89)607  fina.l.,  SYN  231 .of 26 Ja.nua.ry  1990). 
·  Pursuant to Article 149(3) of the ~-Treaty, the Commission has deeide:i to·· 
make  16 aroen:llnents  to its proposal  . 
. The Commission has aroepterl the two .amen:irnents clarif'ying the definitions 
of terms use::l in the proposal,  the amerrlrnent stipUlating that only the 
excipients that should be known about to ensure safe ani effective use of 
the me::licinal product nee::l  appear on the l.a.bel ani the a.rnerrlroent  removing 
the obligation to in:licate the name  of the manufacturer, if other than the 
person responsible for placing the product on the market.  It has not 
include::l . the other arnen:::'lrnents  on labelling,  since care must be taken to 
avoid putting too much  on the l.a.bel ani rrak:ing it impracticable for 
manufacturers or incomprehensible for consumers. 
The Commission has include::l several of the amerrlments adopted by Parliament 
on smaJ..l  outer packaging. 
As regards the package leaflet,  the Commission· has include::l the amerrlroents 
nade by Parliament to bring the text of the proposal into line with the 
.  ·rules on labelling plus two  other major additions:  .. details of the nature 
ani.·expec:ted effect of using the me:licina.l.  product,a.Irl· specification .of the· 
··date on. which the package leaflet was  last revise:i.  · · 
· Fina.ll  y,  two  aroen:iments  to the general guidelines have also been acceptei. -3=-· 
..  Amer.,;,-,;,;-;c;~.  to  .. .the  proposaJ  for  a 
·  . COUNC ll 0 I RECT l.VE' 
·on  the·  l~bell'i ng:of med'i'cl.na I  products·  for·~human'·-use. 
and  on  package  leaflets 
(Presented.by• the  commission  rn  accocdance  .. wHh 
Ar't·tc'le.-.1'49'. paragraph .3  of·  the  EEC  Tr.eaty.) 
.Qr i'g:ina I  proposal  Amended· ·proposa I 
TiAels and visas  unchanged 
Rae i ta:l s  unchanged 
.  CHAPTER'  1· 
Scope·and def.inltions 
Article 
!.  This  Directive. deals  with  d\e  Llbdling· of medicinal 
pnhlue~s lor hum:111 .use :1nd  k:lfk•s ·inscncd in p.1ckages of 
such  prod1~o.:ts. 
1  For  1hc  puqHtSc'S  ,,j  1his  DircCiive,  du: dt;finiiion of 
.·,lll·,li..:in:tl  produet'  Llid· down  in  Ar-~iclc::  . .t.  of  Directive 
(i.)I(,.)!EEC sll:lil :1pph. In  addi1ion 10 1.his: 
- "name  of  the·  medicinal  product" 
shall  mean  the  'name  given  to  a 
medicinal  product,  which  may  be  an 
invented  name  or  a  common  chemical 
name  together  with  a  trademark  or 
the name  oE the manufacturer; 
'common  n:lnlc·  ,;h:tll  mc.111  the  imern:uion:~l 
non-propricLir)'  11.1111<'  rcconunendcd  hr  the:  \Vorld 
Health Orf::lllit.:llion. or. i( Ollc' docs not exist. the· usual 
COIH111(1JI  1\;IJtH.•, 
'irnmeJurc· p:1ck:t!:in!!· sh:tllrnc·an d1e com:tilll'r or mher 
form  ot'  pacl.:agi11g  inu11cdiatdy  in  contan  with  the 
mcJicin.1l  prodw:r: 
'o111a p.td.:.•J:ing' ,lull •ncanthc p:~~.:kaging inw "·hich is 
pl:~eed dtl' lllllltc·di.ttl' -p.•c·kagin~:. 
'p.Kk.l!;<'  lc:dlci ·  slull  mean  a 
inform:11ion  for  th<·  u-;n  which 
mcdi.:in:d proJuc1 w  "'hich it  refers. 
leaflc·r  <:wtr.linint; 
accomp;uues  dtc 
I.  This  l)irl'(t II'<'  d~:ds with  the~  labclling.'of mc.:licinal 
procluciS t'or  hum.l;! "'"' :tnd lc:tflc:1s insci'icd :in p:tck:tg'c:s.o( 
such proJu.-rs. 
1.  For  dt<'  f'llf('•>'<'S  ol this  Dir<'..:tivc,  tlte·dd;nition of 
'mcclicin:d  produ.::·  l.tid  down 'in  ;\rticle I  ·of  Dirccti,·e 
65/GY/EEC ,;lull  .l:';•k.  In' addition to this: 
- "name  of  the  medicinal  product" 
ohall  mean  the  name  given  t·o  a 
medicinal  p~oduct,  which  may  be  an 
invented  n<'-·:H?  or  a  conunon  chemical 
name  togeth0r  with  a  trademark  or 
the  name  o:  the·  manufacturer;  in 
the  case o:  an  invented  name,  this 
;~h~'!.!l_.!!.9.!=  ...  _~~.·-'  ..  _.~onfused  with  the 
common  name; 
'common  n.1na·  sh:tll  mc.tn  the·  'imc:rn:ttion:tl 
non-proprict.1:\  n.tlll<'  rcco1nmc:nded  by  the  \Vorld 
lic:tlrh  Or~::tno.'.H•oil,or, if one docs not exist, the usu;tl 
COU11110U  ll:lrll<.'. 
'immc·,f!.uc  p.l~:..~,:in!!· sltallmt·.tn the cont:lincr or other 
form  of  p:td.:.l~trtg  immediate·!.- in. cont:ICI  with  the 
mt·dicin .  .J  pr.•J"'': 
'outer p.lcl.::t)!ut{ .;h.tllml'.lll the p.11.:bging.into whidt is 
pl.tn·J dH·  iuun<·,!..uc·  p.h:kaginl!: 
'p:td.;.l!!<'  lo:],.,·  -;h.tJI  IIIC.IIl  ~ 
inform.uion  tn:  d1c  user  wludt 
mcdicin.d proJu,·t 10 which it  rd<·rs. 
leallc:t  com:tmin,; 
accomp:tnics  1 he 
"labelli:1g~  shall  mean  the 
particula!'s  or:.ovided  on  the  ou.ter 
or  immed ia:e .packaging;  .. 
.'- -~. t 
- ..  ~ 
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Original  proposal  Amended  proposal 
\  Article  2  unchanged 
CHAPTER  II 
.·Labelling. of •medicinal  products 
Article  3 
;-The  following  p:~rticulars  shall  ;rppe;u  on  the  omcr 
1  p.1cka~inp. <Ji medicin;rl products or, where rhere is  no oli!<T 
r  packa~in~. on the immediate packaging: 
(a}  the name of the medicinal product, including or followed 
by rhe common name if the product conr:tins onlr one 
:tcti,·c ingrcdiem; 
_(h)  :t  st.1temcm  of  the·  acti,·c  ingredients  expressed 
qu:rlitatin:ly  and  qu:rntit:ui,·elr  per  dosage  unir  or 
:~ccordin~ to  the  form  of administr:uion  for  a  !!"'<'11 
,-olume or weight, using their common names; 
(c)  the ph:nmacemical form and the comems by weight,  b~· 
vnltrmc or number or doses of the product; 
d)  a  list of  the excipients; 
(e)  the route :rnd method of :tdministr:rtion; 
\()  :1  sp.:.:ial warning th:n the product must h.: stored our of 
rc:rch  o( children; 
(g)  the c'pin· d:11e  in  clear terms (momh/yc:tr}; 
,(h) _spcci:d  Stllf:rg<:  pre.::rutions. if :mr; 
I 
(i)  spcc"ial  precamions  for  disposal  of  unused  medicin:rl 
prodill'tS or \v;rsre m:ueri:tls deri\'ed from·such produc". 
if appropriate; 
.j)  the  name  and  address of  the-person 
responsible  for  placing  the 
medicinal  product  on  the  market 
and,  where  different,  of  the 
manufacturer; 
(k)  chc  nunrb.:r·of rlre  authorization to put.dre medici11al 
prod  lKt  011  r  he m.uket; 
The  followin_!:  p.uticul:us  shall  .tpprar  on  the  omcr 
p;r.:kaging of mcdi.:in:rl products or. "·hnc tht•rt• is  no outn . 
p:tcbging,·on th<'  immcdi;He  p;tck:rgin~: 
(:1)  the name o( the medicinal produc1. induJing or (ollownl 
h}·  rhe common name i( th~ produ..:t  .:onr:rins only on<' 
:rctive  ingr~dicnt; 
(b) a  sr:rt<'lllCnt  of  the  acri''<'  in~retlicms  c~prc,scJ 
qualit:tti,·eh- antf qu.1ntit:ni,·.·h·  per  dos:rgc  tniLt  or . 
:rccordin~ to  the  form  of :rdministr:uion  for  :1  !!"'<'11 
,·olume or W<'i!!ht,  using thrir comnwn 11:11nes: 
(c)  the ph:rrm.r,·t'uti,·:tl form :md the c<Hlll'lliS ["· "·c,_,:hl, !·:· 
,-oltiiiiC' or nu:rrl'cr or dos6 oi dw pro,h'"; 
d)  that  should  be  the  cxcipients 
kno,.:n  about  to  ensure  an 
effcct~  .. ·e  use  of  the  medicinal 
Qroduct; 
(f)  :1  spn:i:tl  ,;,.·.1::;1n~ 1h;H thl' pro  .. lu  ...  ·t 111tl':  l,  ...  ,Hut·,i oul <': 
rl':h  .. ·l,  of (hikirc:n; 
(;:1  tht: expiry ,h!c in  clc;tr terms (III<HHh;,,·_rr): 
(i)  Spt·  .. :i:•l  prt.·  ... ·.Hulons  for  dispos.d  of  unu~cd  llh  .. ·o.iH  .. _.in.ll 
Jlloducts. or''  .l~tl~ rnatt~ri.•ls dt..·rr,·t·d  iron1 ~ud1 pro~luct'. 
i( .1ppropri.u:·: 
. j)  the  name  and- . address 
person  responsible  . for 
the  medicinal  produ  ~ 
market; 
of  the 
placing 
on  the 
(k)  the  lllHUha ,,1  rh~·  audwrit.:uion  10  1'111  tla·  ouc.loc·in.d 
product 011  dot'  m:trket; 
[I)  the tuauuf.H:Itlrer's b;uch number. -5:-
··  .'~,-.. Or·l·ginal'  propo~al-
.  1.  The·  .·fol-lr.~;~i'ng  -par.t·iculars  eha11 
··appea·r:·.  ''l'.lfi',- .immediate  packagings 
. placed  in  a·r.  outer  pacKaging  which· 
. compLies  wLth  the  .requirements 
laid down  Lr.  Article 3: 
name of rhe medicinal product, 
r  ;_  . 
quantity of acrive consticuems, using common names. 
route. and method of administr:l!ion, 
expiry dare, 
batch number. 
2.  Paragraph·  1  shall  not_  apply  to 
i!lUllediate  packagings  containing  a 
single .dose._.which  are  too  small  to 
contain all the particulars  listed 
in  paragraph  1. 
...  .Amended' proposal  ..... _.,  .-:· 
~ 
l..At  lea·s·t:  t·he·  ,''follow'ing 
·particulars  'shall·-. a·f?pear··. ·on 
immediate •packagi.nga: p'Iaced·'i-ri· a'n 
outer  packaging  whi'ch  complies 
with  the·  requirement.e  Laid  down· 
in Article 3: 
name ot the medicina'l product·, 
quantity of active constituents. using common nameL 
rotue and method of administration, 
expiry J.uc, 
b:uch number. 
2.  I!lUllediate  packagings  which  are 
too  small  to  carry  an  the 
particulara  listed  in  Article  3 
shall  carry  at  least  the 
follo•:ing  part  i·cu la  r-s: 
- name  of  the  medicinal  product, 
route  and  m~thod  of 
administration, 
- expir-y  date, 
- batch  number, 
- contents  by  weight,  by  volume  o~ 
by  number  of doses. 
3.  Immediate  packagings other  tha~ 
those  referred  in  paragraphs 
I' 
1  and  2  shal I  carry  the 
particulars  laid  down  in·  Art.icle  3 . 
.  ·:.:· -6-
Original  proposal  Amended  proposal 
Article  5  and  6  unchanged 
CHAPTER  Ill 
User  leaf let 
Article 7 
The  inclusion  in  the  ·packaging c  of 
medicinalc  products  of  a  package· 
leaflet  fo;:  the  infOCfiaation  O[  users 
shall  be  obligatory. 
information  required 
directly  conveyed 
packaging  or  on 
packaging. 
unless  all  the 
by  Article  8  is 
on  the  outer 
the  immediate 
The.  inclusion  in . the  packaging  of 
medicinal  products  of  a  package· 
l~aflet for  the  infocmation  o-f  user:; 
shall  be  obligatory  unless  all  the 
information  required  by  Article  8  is 
directly  conveyed  on  the  outer 
packaging  or  on  the  immediate 
packaging  or  unless  the  medicinal 
product  may  be  administered  only  by 
a  health professional. 
Article 8 
1.  The  leaflet shall  include,  usually 
in  the  following  order: 
a)  for  the  identification  of  the 
medicinal  product: 
name  of the medicinal  product 
quant it  at ive  and·  qual it  at ive 
composition  in  terms  of  active 
ingredients,  using  the  common 
names, 
i(  pharmaco-therapeutic  group, 
there  exists  a  term  easily· 
comprehensible  for  the  patient, 
1.  The  leaflet  ghall  be  drawn  up  ir. 
accordance  with  the  summary  o! 
product characteristics;  it shall 
contain,  usually  in  the 
following order: 
a)  for  the  identification  of  the 
medicinal  product: 
name  of  the  medic ina  1  product 
in  accordance  with  Article 
llll..t. 
full  quantitative  and 
qualitative  composition  in 
terms: of active  ingredients  and 
excipients,  uoing  the  common 
names, 
pharmaceuticalcform  and  contents 
by  weigh:~  by  volume  or  by  dosaae 
~. 
pharmaco-therapeutic  group.'  Q..:.. 
type of action,  if there  exLsts  a 
term  easily  com-prehensible  for 
an  the  patient,  or,  if  not, 
indication  of  this  category  in 
f  ·  ·  · 1  description  of  terms  o  a  sLmp  e  _ 
what  it covers Or iginat  proposa5 _ 
n:;me  and: adi.h:~-ss uf die hoMer of d1c- markc:li'n~-: 
authorization.  and,  where  different,  of  t·Fte 
manufactun.T;-........ -
(b) the therapeutic indic:uinns;. 
(c)  a  l'ist  of information. whidi  1s  useful' before taki'ng  a 
medicinal' product: 
comra-indications,. 
appropriate precautions for usc, 
interactions with other medicinal products and other 
forms of interaction (for example, alcohol, tob:icco) 
which may affect the usc of the mcdici'ne, 
special warnings, 
this lisr  must: 
take into account the panicubr condition of ccn:1in 
categories  of  users  (e.g.  children,  prcgn.1nr  or 
brcastfeeding  women,  the  ddcrly,  persons  with. 
specific p:1thologic:d conditions), 
mention,  if  appropri:11~.  p<ne<Hial  effects  on  the 
ability to drive vehicles or to operate m:Khinery, 
refer  to  1hc  excipient:>  knowkdgc  of  which  is 
import  am for :a  safe :md c·fkcti\'e usc of the medicinal 
product; 
d)  the  necessary  instructions  for 
proper use,  in particular: 
the· usual  dose  and  maximum dose, 
the  and  of 
administration, 
the  frequency  of 
specifying  i.f · 
appropriate  time 
medic ina  1  product 
be  adrnini'stered; 
administration, 
necessary  the 
at  which  the 
should  or  must 
and;  as  appropriate,  d'epending  .on 
the  nature of  the product 
-7-
Amended pr  opos.a: li 
o;lmc.  ;~utf. :ul'dr.·ss· ttf the·  IH·tli.Vcr.·  uf the·  11o:1rkeri;nt-: 
aud\ori-1.·:•rion.,  and'.  where  di~f"c't'cnr.  of  the 
--nr:umfacnn:cr.; 
'(c):  :1>  list of ii•fotm:ni.liln'  wl11ch  is  mcful' hdnrc  rakin~ a 
medicinal' product: 
com  ra-ind'icati(;H1S, 
appropriate prec·;unions· for  usc, 
imcractions wirh other medicinal proJu.::rs· ;;nd other 
forn~s of imeracrion (for cxampk. ak<•hol, tob.1cco) 
which may affcCI  tlu:  US<'  of the mnlici<le,. 
spcci:~l warnings. 
this list  must: 
rake intt> .tccount the p.<rtt.::ul:u  condittlln <J( Cl'rt,1in 
c:ucgori~~  t.lf  users  (c .. g.  chiiJr.cn~  rrL·:.:u;uu  or 
brc.1stfcc-iing  \\'Omen.  the  dderh·.  l'<'rsons  \\'ith 
spc.::ifi.::  p.Hhologic.ll .::nn,litt<l<b). 
rncnri<.lli.  if  approprt.Ht..',  p<H~nri.ll  l.·ffc  ... :ts  4..lll  th<.: 
ability""' drive  ,-chi~.,-1(·..;;  pr to  op<.:r.lh: 1ti.1.:hincry. 
refer  (._l  rhc  <:~l..':ijlll'l;i...  knowll.·dg~.:  d{  \\'hich  lS 
i111p,Ht.:::r for ;I  S;t f~  .. 11h! ,:t ft..'~l j \'l' U".;.'  c lf I h<. .. lllt  .  .'l..iii...·jn;ll 
pro;lucr; 
d)  the  nece·aoary  instructionso  for 
proper  use_,  in  particular: 
the  usual  dose,  together  •.:ith 
wordi~q  indicating  that  this 
does  not  apply  for  different 
doses  being  prescribed,  andi  if 
possible,  the  maximum  dose 
toget~er  with  a  warning  that' 
the  dooe  and  therapeutic 
procedure  may  be  modified  by 
the  p:-escr iber; 
the  method  and  route  of 
administration, 
the  frequency  of 
administration,  speci..fying  if 
necessary  the  appropriate  time 
at  ~-·~i.ch  the  medicinal  product 
should or  must be  administered; 
and,  as  a;?rop:-iate,  dcpendLng  on 
·the  nature of  the  product e) 
·or ig i'na 1  · proposa  1  ···  .. ,  ···· 
the duration of treatment,  when  it 
should  be  limited, 
·the  action  to  undertake  in  the 
case  of  overdose  (symptoms, 
emergency  procedures,  antidotes), 
the  course  of  action  to.take when 
a  dose  has  not  been  taken, 
the  way  the  treatment  should  be 
.stopped·,  if stopping. the treatment 
may  lead to withdrawal effecto; 
a  description  of  the  undesirable 
effects  which  can  occur  under 
normal  use  of  the  medicinal 
product,  with  indication  if 
posoible  of  their  importance,  and 
if  necessary  the  action  to  be 
taken  in  such  case;  if  the 
medicine  is  new,  the  patient 
should  be  expreosly  invited  to 
communicate  any 
which  is  not 
leaflet  to  hie 
pharmacist; 
undesirable effect 
mentioned  in  the 
doctor  or  to  h iu 
(f)  ;~  rdcri:ncc w  the  c~pirr .tuc 'indi.:atcJ  on the bhd. 
with: 
;t  warni111:  a1:ainst  using  th<·  produ<t  :1fta  thi' 
date, 
where appropriate, special storage precautions, 
if  nccesS.1r)'  a  w;lrning  against  "isiblc  signs. of 
deterioration; 
(g)  all  other inforniation comp:uihlc with the summar)' of 
product chactctc:ristics of the product, u\cful for hcahh 
education,  and  on  condition  th;11  it  is  not  of  a 
promotional n:trurc. 
-8~ 
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the duration  of  treatment,  when 
it ohou'ld  be  Limited, 
the  nat~re  and  expect~d effect 
of using  the medicinal  product, 
the  action  to  undertake  in  the 
case  of  overdose  (symptoms, 
emergency  pro·cedures  and 
antidotes  where  they  exist 
together  with  an  express 
r~commendation  not  to  use  them 
sxcept  y~dar medical control), 
the  course  of  action  to  take 
.when  a  dose  has  not  been  taken, 
the  way  the  treatment  should  be 
stopped,  if  stopping  the 
treatment  may  lead  to 
withdra~al effects; 
e)  a  description  of  the  undesirable 
effects  which  can  occur  when  the 
medicinal 
ind·ic.at ion 
?roduct  is  used,  with 
if  possible  of  their 
and  if  necessary  the  importance, 
action  to  be 
the  patien::: 
invited  ::o 
undeoirable 
taken  in  such  case; 
should  be  express  1 y 
ment i.oned  in 
communicate 
effect  which  io 
the,  leaflet  to 
doctor or  to  his  pharmacist; 
any 
not. 
his 
(f)  :o  rt•fn<'lk<'  t••  :!w  ,·,pin d.ll<'  ondK:Hc,i  011  the  Ltbd. 
1\'lth: 
:1  ".Hnllo!:  .o,:.unst  u\in,:  the  produ.:r  :.fter  this 
d.H<'. 
\\'IH:u· .1pp: ·•t'ri.Hl".  'P\'Li.ll  "i[Of ;I gil'  pr<.'CHitiOr1'\, 
if  tH.'(t'''·ll'  ·'  ,,.,1rnin!~ ..  l~.1irP.;(  \'i.,ih1c  si~rh  of 
dclcrior  .H "l;'!: 
(g) ;til  mher inforr.;.uion .:ornp.uoblc with  the summ:trr of 
product ch.H.t.-;~ri,ti.:s of the product, usdul for he lith 
cduc;ttion.  .tn-:  <.HI  conduoon  th.u  it  i~  nm  of  .1 
promoti111ul o:,:c:r,·. 
1)  the  date  on  which  the  package 
leaflet  was  last·. revised 
. J -···-----------.  -·· ·····-·  .............. .. 
;f: ...  ,. ........  '  •  ···~  ....... ·-~~  ------- >.-......... . 
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Original  propo$al  Amended  proposal 
Article 9 
The  package  leaflet  must  be -written 
in clear·and understandable terms  for 
the patient,  in the official language 
or  languages  of  the  Member  State 
where  the medicinal product  is put  on 
the  market.  This  provision does  not 
prevent  the  leaflet  being  printed in 
several  languages,  provided  that  the 
same  information  is  given  in all  the 
languages  used. 
-·The  package ·leaflet .must- be  .. written  . 
. in  such  a  way  that  it  i's  cle.2!.'. 
easily  legible  and  underPtandable 
for the patient,  in the official  language 
or  languages  of  the  Member  State 
where  the medicinal  product  is put  on 
the  market.  This  provision  does  not 
prevent  the  leaflet  being  printed  in 
several  languages,  provided  that  the 
same  information  i.e  given  in all  the 
languages.used. 
Article  10  unchanged 
CHAPTER  IV 
General  and  final  provisions 
Articles  11  and  12  unchanged 
Art i c I  e  13 
As  necessary,  the  Commisaion  shall 
publish guideline& concerning: 
the forllluLnion of ccnain w:unings for certain cuq;orics 
of medicinal products, 
the  particular  inform:nion  lll'cds  rcl:nivc  to 
sci f-rnedication. 
the  rcadahilit)'  of  particuLus  on  the  lahcllillg  and 
lea Oct. 
ll!ilit.:nion of h:tr co,ks for till· idnuifoc·.uion of nwdil·in:d 
J'H>UliCI'i. 
For  this  l'"'l""l',  dll·  Conunis,ion  ,hall  con,uil  the 
Con111;illl"e for l'rnpril't:try :->kdicin.tll'tnducts institutl·d h)' 
Dirl·c·tivc 75 I Jl  '1 I EEC. 
No  later  than  two  years  after  the 
adoption  of  this  Directive,  the 
·Commisaion  shall  publish  guidelines 
for  the  various  leaflet  sections  in 
particular concerning: 
the fornuJLHnHl of  <:t·rtaio w.Hnir:t:' for f.."l'fl:llll  L.H<:t..:on~.·:-. 
of mcdicit!.!l  products.  .  . 
tht·  p.1rt1.:ul.tr  infonn;l(ion  llt'•.:d:-- rcl.lfi\T  h' 
sclf-m<'doc.t:oun. 
tht•  rt·aJ.d,i!::\  of  p.tnu..:ul.ar"  on  du.·  l.thdl 111 ~  •111J 
k.otll·t. 
llliliz;UIOfl tl~ J'.lr l'ffdt.'"' for 1fa1.:  ldnlllfH:.UI(IIl o( IIIClfj(jll.d 
produt·t,. 
excipients  that must  be  indicated 
on  the  packaging  and  warnings 
referring  ·to  them  that  must  be 
carried on  the  packaging. 
Fur  thi~  pur;"• "'".  du:  c·,,ntr111"1''"''  ,h,dl  l tllhuiC  1hc: 
(~UIIllllllh't,: for  l'r~'prlcl.lf~' ,\h:du  ... ·ill.d Pr{1du  .. :1' lll,trtuteJ ~~ 
Dirl·..:tin· 7) /31-l : u:c. · 
Articles  14,· 15-and  16  unchanged 
.  .. Amendment  to  the  proposa I  for .. a 
COUNCIL  DIRECTIVE 
on  advertising 
-:of medicinal  products  for  human  use •  -·  -':;"".  4  ',  ••  p  o;'  ...  ..~ 
••. "!.'  ""-... 
,.  ~  ~ .  ~  - .  ...........  -.··· 
-2;--
·At· its plenary session  .. on 12 JUne 1991: the  .. European.:Parliament :aJ?prOV:ei~:the·;·  ...  :..  ) 
Conunissibn'·proposa.l ·on· advertising of me:iicin&L prod.ucts. for --human  use·· · : 
(COM(90)212  f.ina.l,  SYN  273: of 6  June·1990). 
PUrsuant· to!.Article 149(3) of the E::EC' Treaty.· the. Cbmmi.ssion has. decidei·  .. to·· 
rcake.  19 ame:rx:llnents  to · its proposaL 
The Commission has ~tei  the ameniments prohibiting advertising. to the. 
-~..~  . 
. general. public of rnei:l9ina.l products· which a.re habit-forming ani/or 
addictive.  of performanoe--enbanci products or of meiicina.l. products 
subject to reimbursement by the social. secuxi  ty system.  It has a.l.So 
acceptei .the. amendmen~ prohibi  t:ing the distribution of free gifts ani 
bonuses ani l1l8klllg  it.·'~ory  · to include an express instruction to read . 
· the label and the package .leaflet ca.ref'ull  y...  The other a..rnerrlments  on 
~:; 
advertising to the g~aJ. public have not been includei:  the Commission 
;~' 
feels that ·there is nri  nee:i for a  Conumm.ity  Directive to lay down  the 
sma.llest details  .. on ~  advertising of meiicina.l products,. where such 
· advertising is allowei. 
As  regards  advertis~~  to heal.  th care professionaJ.s.  the amerrlei proposal. 
includes the amendment~ omitting the exception for objects of an 
insignificant intrins~~- vaJ_ue  ani incorporates the rules proposei by 
Parliament on the  spo~orship of scientific congresses.  However,  the 
Commission could not accept the prooe:iures advocatei by Parliament to 
monitor this point.  As  regards the measures to control free samples,  the 
Commission felt that' i-t was  inappropriate to replace the quantitative 11mi.t 
which it  had prop0sai by a  time limit. 
Finally,  the Conunission has acceptei none of the amen::lrnents  on moni taring 
and penal  ties.  Since ,,the rules proposei have been ha.rmonizai with the 
existing Comrmm:i. ty Ieg,j,.sla.  tion it saw  no nee::l to depart from  them. 
9-:1... 
""'1· (. 
;. 
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Amendment  to  the  proposal  for  a 
COUNCIL  DIRECTIVE 
SYN  273 
on  advertising 
of  medicinal  products  for  human  use 
(Presented  by  the Commission  in accordance  with 
Article  149  paragraph  3 of  the  EEC  Treaty) 
Original ,proposal  . Amended  proposal 
Titel  and  visas  unchanged 
Three  first  reclta·ls.unchanged 
Fourth·recital 
Whereas  advertising  to· the·  genera  1 
public  even  of  non-prescription 
medicinal  products  could  affect 
public  health,  if  it  was  excessive 
and  i 11-considered;  whereas 
-advertising  of medicinal  products  to 
the  general  public:,  where  it  is 
perm i t ted ,  ought  therefore  to 
sa·r1sfy  certain  essential  criteria 
which  ought  to  be  defined; 
Whereas  advertising  to  the  general 
public  even  of  non-prescription 
medicinal  products~ affect  public 
-health,  if  it  does  not  satisfy 
cert•in  essential  criteria  which 
ought  to  be  defined; 
Fifth, sixth  and  seventh  recitals unchanged 
Eighth  recital 
Whereas  persons- qualified  to 
prescribe  medicinal  products  must  be 
able  to  carry  out  these  functions 
objectively without  being  influenced 
.by  .direct  or  indirect  financial 
inducements; 
Whereas  persons  qualified  to 
prescribe  medicinal  products  must  be 
able  to  carry  out  these  functions 
objectively  witho~t being  influenced 
by .direct or  indirect  financial  - or 
other  - inducements; -4-
·  Or i.g ina I · p_roposa I  . · · · ·  Amended. proposa I 
Ninth  recital 
.·•·  '  ·  Wherea·s··'i't  s.houJd  .be  possib.le  wi.thi·n ·. 
certain  restrictive  conditions·  to 
p r·o vi-de  ·s anip.l e·s·-· ·  o.f  ·medic  i.n a·l· 
•····  -· •  ·pl':'oducts: free ·of .. char.ge · to  .persons 
·  ...  -.  ~- ··  .. qual.i f-i ed  ·~to.·  pres·c.ri b_e·:  ·o·r  . supply 
· •·  .-.'them  so-~that  they·  cari. fami.liar:1ze' 
·.t·hemselves  "Wi·th  new  products  and 
acquire  experience  in  dealing  with 
them; 
.·,·.  Whereas  i-t ·should. be·-possi·ple.>wi-th·in, · 
certain  restri·ct  i ve·  ·c0ndi:tions .... ·to 
provide  -:s·amples  '-~·of.·.me.d.icin:a·1.o 
product  sc·. fr.ee .. of  .. ,-ch-a r:-ge .·:t-o··. pe rson·s:,  .  .  ."-''  •. 
qua·l i f.i.ed  .. :,to, :.prestr:U~~ .'_·or. :.supply:. 
.them  .so.  th-at.  they  .:can  .  .T.amJli,ariz.e. 
themsel~es  with.  new  .~roducts  and·. 
acquire  exper.·ience  in :dea.li-ng·  with· 
t h e.m ;  t h e s e  f r e e  · s a m  p 1 e s  o f 
medicinal. products  must,  .of  course; 
not· be  so  1 d ;· 
Tenth:and  el~venth recital• unchanged· 
·Twelfth  recital 
\-Jh ere  as  each .  undertak; n'g  which 
manufactures·' 'or  imports  medi.cinal 
products  sho'ul d  set  up  a  mechanism· 
to  ensure  ·that  all  information 
supplied  about  a  medicinal  product 
co·nforms  with  the  ·approved 
conditions  of  use, 
Whereas  each  undertaking  which 
manufactures  or.  imports  med~cinal 
products  should  set  up  a  mechanism 
to  ensure  that  all  information 
supplied  abou.t  a  medicinal  product 
corresponds  to  the  i·nformat-ion 
provided  in  the  summary  of  the 
characteristics  of  the  product,  as 
approved  by  the  competent 
authorities; 
CHAPTER  I 
Scope,-definitions and  general  principles 
Article  1  unchanged 
Article  2 
1.  Any. ad,·enising of a _m~~icinal product 10 respect ~f 
which a marketing authonzatlon h_as  not ?~en granted 1n 
accordance with Community law  IS  proh1b1ted. 
'2...,  All  parts  of  the  advertising  of  a 
medicinal  product  must  be  compatible 
with  the  particulars  listed  in  the 
.summary  of product  characteristics. 
I.  Any advertising of a  m~dicinal product in  respect of 
which a  marketing authorization has not been granted in. 
accordance with Community law  is  prohibited. 
'1..  All  parts  of  the  advertising  of  a 
medicinal  product  must  conform  to 
the  particulars  ...  (rest  unchanged) 
·.) .  l 
() 
Orig'nal  proposal  Amended  proposal 
CHAPTER  II 
Advertising  to the  general  public 
Article  3 
I.  Member Sta·.es  shall  prohibit the ach·en_isins  to the 
general public of: 
.  .  d  h'  h  · n  psvchotropic  or  med1cmal  pro  ucts  w  IC  contal  .  .  .  . 
.  b  · h'  h  eanin" of the mter- narcouc su  stances, w1t  1n  t  e  m  o 
national conventions, 
.  .  ·  d  1  • 1  re  oniv available on  - other med1cmal  pro  ucts  w  11c  1  a  ;  .  .  . 
.  prescription,  in  accordance  with  Council  Dlrecuve 
.. .1 .. .IEEC. 
2.  Member St:nes sh:.ll  prohibit the mcmion in  adver-
tising tO  the gener:1J  rubJic of thcr:tpt·~tiC ind_ICaUOnS  for 
which  self-medic:~tion is  nm sui!ablc,  111  p:~rucu!Jr: 
- wberculosis, 
- sexually transmitted  di~t·a~c~. 
- other serious infeniou~ di~casn, 
-cancer, 
- chronic insomnia, 
- diabetes and other metabolic illnesses. 
3.  The prohibition referred to in  para~;raph I shall not 
apply  to  \'accination  camp:~igns  approved  by  the 
competent authorities of the  Member St:Jtes. 
4.  The prohibition  referred in  para~;raph 2 shal_l  ap~ly 
without  prejudice  to  :\niclc~  2,  3  and  14  of  D1reCU\'e 
89/552/EEC. 
S  Me  b  S  h  1.1  Prohibit the free distribution of  .  m  er  tates s  a  .  . 
··medicinal  products  to  tlu::  public  for  promouonal 
. purposes. 
I.  Member States shall  prohibit the  advenising to the 
general public of: 
- medicinal  products  which  contain  psrchotropic  or 
narcotic substances, within the meaning of the inter-. 
'9ational con,·emions, 
- .(i.iher  medicinal products v.•hich  are only available on 
prescnpt1on,  in  accordance. with  Council  Directive 
:\ ./  .. .IEEC.  ., 
.medicina:l  products  and  products 
which  are  habit-forming  a11d/or 
addictive, 
any  performance-en~ancing drug  or 
product,  'as  defined  .by  the 
Counci 1  of  Europe  and  the 
International  Olympic  Committee, 
medicinal  products which 
are  reimbursed  by  the  social 
security. 
2.  ~!ember S::~1es sh:tll  prohibi1 the memion in  ad\·er-
tising  to the g(nc-rJI  puulic of therapeutic indications for 
which  scli-medication  is  not suitable,  in  panicular: 
tuberculosis, 
sexually transmiut·d diseases, 
- other serious infectious diseases, 
-cancer, 
- chronic insomnia, 
- diabetes and other metabolic illnesses. 
3.  The prohibition referred to in  paragraph  I shall not 
apply  to  \'accination  campaigns  approved  by  the 
competent authorities of the  Member States. 
4.  The prohibition  referred in  paragraph 2 shall  apply 
without  prejudice  to :\nicles  2,  3  and  14  of  Directi\·e 
89/552/EEC. 
5.  Member-s  States shall  prohibit 
the  free  distribution of 
medicinal  products  to  the  public 
for  promotionai  purposes, 
as  well  as  the offering of  30 
gift~ or  bonuses~ -6-
.  or igina &·proposal·  Amended  proposal 
Article 4 
Without  prejudice  to  Article  3. all  2_dvenising  to  the 
g_eneral  public  __ of  a_me~icina~_pr()()~~t- s~all:  _____  : __  _ 
t  ,·n  such  a  fashion  that  a)  be  set  ou  . 
it  is  cle.ar  that  the  message  1S 
an  advertisement.  and  t~a:  the 
d  t  is  clearly  identlfled  as  pro  uc 
~medicinal  product, 
(b)  include the following minimum information: 
the name of the medicinal product, incorp~rating 
or  followed  by  the  common  .name  If  the 
medicinal  product  contains  only  one  acuve 
ingredient, 
the  information  necessary  for. co_rre~t  usage  of 
the medicin:tl product, such :ts  mdl~~uons f_or  use 
:tnd ·  speci:tl  precautions,  or,  f:t1hng  this, tn 
express  invitation  to  re:td  the  p:tck:tge  le:t  let 
carefully  .. 
Without  prejudice  to  Article  3,  aU  advertising  to_ the 
gen~ral public of a  medicinal product shall:  · 
a)  be  set out  in  such  a  fashion  that 
; t  is  c'\ ear  that  the  message  -, s 
d  rt, . sement  -and  that  the  an  a  ve  • 
product  is clearly presented  as  a 
medicinal  product; 
(b)  include the following minimum information: 
the name of the medicinal product, incorpor:ning 
or_  followed  by  the  common  name  if  the 
medicinal  product  contains  only  one  active 
ingredient, 
the  information  necesSal")'  for  correct  usage  of 
the medicinal product, such J.S  indications for use 
:1nd  special  precautions,  -
an  express  invitation  to  read  the 
label  and  the  packaCie  leaflet 
c'arefull y". 
Article  5 
The  ad\·enising  of  :1  medicin:tl  p~oduct_ to  the  gem·ral 
public  sh:1ll  not conl:lin any m:ttenal  whiCh: 
(a)  !!i\·es  the  impression  that  a  medical_ consul~ation or 
..  1  b\.'  surgic:~l  operltion  is.  unnecessll")', _m  parucu ar 
offering  3  di:~gnosis  or  by  suggesung  treatment  by 
mail; 
b)  suggests  erroneously  that  the 
.effects  of  taking  the  medicine 
are  guaranteed,  or  are  better 
than  another  treatment; 
(c)  sunnests  th:u  the  nom1al good  health  of the subject . 
ca~\e enhanced  by  takin~;, the  medicine,  or th.:n  It 
could be  :~ffected by 'not ukin·g the medicine; 
(d)  is  directed solely or mainly at children; 
(e)  refers  to  :1  recommendation  by  scientistS  or  he:llth 
professionals; 
(f)  suggests that the  medicinal product is  a  foodstuff or 
:1  cosmetic, or vice versa; 
(g)  suggest;. th:lt  the safety or efficacy of the medicinal 
product is  due to the fact that it is  'natural'. 
The  advertising  of l  medicinal  produet  to  the  gener:li 
public shall  not contain any mlterill which: 
(l)  gives  the  impression  thlt  a  medical  consult:nion  or. 
surgical  oper:1t10n  IS  unnecessary,  1n  panicui:lr  b\' 
offering  a  di:~gnosis or by  suggemng  treatment  b\· 
m:~il; 
b)  suggests 
the  effects 
medicine 
better 
are 
than 
of 
that 
taking  the 
guaranteed,  or 
the  effects 
are 
of 
another  treatment; 
(c)  suggests that  the  normal good  health  of the subject 
can  be  enhanced  by  taking the  medicine,  or thlt It 
could be affected by not taking the medicine; 
(d)  is directed solely or mainly at children; 
(e)  refers  to  l  recommendation  by  sc1enusts  or  he:~lth 
professionals; 
(f)  suggestS that the  medicinal produCt  is  a  foodstuff or 
a cosmetic, or vice versa; 
(g)'  suggests thu the  s:~fety or efficacy of the  medicinJ.I  · 
product is  due to the fact that it is  'n:~tural'. · 
.)---
) 
I 
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Original  proposal 
'·.  ,'  ··Amended  proposa.l 
CHA~TER Ill 
Advertising to health-professionals 
Article 6 
· An!;  advertising  of 
pr~duct  to  persons 
prescribe  or  supply 
shall  include: 
a  medicinal 
qualif;ed  to 
such  products 
- the  particubrs  listed  m  the  summary  of  product 
...  _:- .. .::~;-,!;tlCS, 
-·the legal prescription status of  the medicinal product, 
the ret:ail  price of the v:arious presentations, 
if  appropriate,  conditions  of cover:age  by  the  soci:al 
security systems. 
2.  The advertising of a  medicinal  product to  persons 
qualified  to  prescribe  or  supply  such  products  may, 
.notwithstanding pangraph  I, include  only  the  n:ame  of 
the medicinal product, if  its sole object is  to recall to the 
latter. 
Any  advertising  of  a  medicinal 
product  to  persons  qua  1 i .fi ed  to 
prescribe or  supply or dispense  such 
products  shall  include: 
the  particulus  listed  in  the  summary. of  product 
ch:aracteristics, 
the legal prescription status ofthe medicinal product, . 
- the retail price of the various'presemations, 
- if  appropriate; conditions  of coverage  by  the  social. 
secunty systems. 
2.  The advertising of a  medicinal  product to persons 
qualified  to  prescribe  or  supply  such  products  may, 
notwithSt:anding  paragraph  I,  'include only the  n:ame  of 
the medicin:al  product, if its  sole object is  to recall  to the 
Iauer. 
Articles 7  and  8  unchanged 
Article 9 
A~  In  the  course  of  promoting  medicinal 
products  to  persons  qualified  t~ 
prescribe  them,  it  shall  be 
prohibited  to  give,  proffer  or 
promise  to  such  persons,  directly 
or  indirectly,  any  gifts,  pecuniar~ 
advantages  or benefits  in  kind,  with 
the  .  exception  of  objects  of  an 
insignificant  intrinsic. value. 
)., In  the  course  of  advertising 
medicinal  products  to  persons 
qualified  to  prescribe  them,  it 
shall  be  prohibited  to  give,  proffer 
or  promise  to  such  persons,  directly 
or  indirectly,.  any  gifts,  pecuni.ary 
advantages  or  benefits  in  kind. 
(rest deleted) or lglnal. Proposal  ·  · 
1.  Persons qualified  to prescribe  or  suppl~ medic~nal 
products  shall  not  solicit  or  accept  any  mducement 
prohibited under paragraph  I. 
3.  The prohibition  referred  to  i~ paragraph  '  applies 
without  prejudice  to  the  reg~latJons.  of  the  _viember 
Sutes  concerning  prices,  profit  margms  and  d1scounts. 
-8-
Amended·· proposal·· 
1.'  Persons  qualified {0  prescribe  or supp1y  medicinal 
pr:oducts.  shall  not  solicit  or  accept  .any  iriducement 
:prohibited  under paragraph  I.  . 
3.  The prohibition  referred  to in  paragran!-:  ·  applies 
without  prejudice  to  the  regulations  of  the  !>1embcr 
States  concerning  prices,  profit  margins  .u•d  discounts. 
Article  9a  (new) 
t  ~  .. 
1.  The  provisions-of Article  9  shall 
'not  prevent  undertakings  which 
produce  or  import  meslicinal 
products  from  ·  organ.J..~r.!..9.. 
congresses  intended  solely  for 
the.  further  scientific  train~ 
of  health  care  professionals. 
2.  In  this  case,  the  hospitality 
extended  to  participants  must  be 
subordinate  to·  the  main 
scientific objective  of the  event 
during  which  it  is  provided. 
Such  hospitality  shall  be 
extended  only  to  health  care 
professionals. 
Article  10 
Where  medicinal  products  are  being 
promoted  to  persons  qualif~ed  to 
prescribe  or  supply  them,  free 
samples  shall  be  provided  to  such 
persons  only  on  the  following 
conditions: 
(a)  two samples at the most may be  pro\·ided every year 
to  any  person  qualified  to  prescribe  or  to  supply 
medicinal productS; 
(b)  any  supply  of  samples  must  be  in  response  to  a 
written request, signed and dated, of the recipient; 
(c)  the samples shall be  identical to the smallest presen-
tation on the market; 
d)  the  samples  shall  be  marked  "free 
medical  sample  - not  for  resale" 
or  with  another  1 egend  of 
analogous  meaning; 
Where  medicinal  products  are  being 
advertised  to  persons  qualified  to 
prescribe  or  supply  or  dispose  them, 
free  samples  shall  be  provided  to 
'such  persons  only  on  the  follo.,.Jing 
conditions: 
(a)  two samples at the most  may  be  provided ever/ year 
to  any person  qu:dified  to  prescribe  or  to  supply 
medicinal products; 
(b)  any  supply  of  samples  must  be  in  response  to  a 
written request, signed and dated, of the recipient; 
(c)  the samples  sh~ll be  identical to the  smallest presen-
tation on the market;  · 
c\)  the  samples 
clearly  and 
shall  be 
indelibly, 
marked, 
'free 
medical  sample- not  for  resale'. 
or  with  another  1 egend  of 
analogous  meaning; 
J.. .. 
original  proposal 
(c)  the  samples  shall  bc.accompanied by  a  copy of the 
summary of product characteristics; 
(f)  no samples of medicinal products containing psycho-
tropic or narcotic  substances within  t~e meaning of 
international conventions may be supplied. 
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Amended  proposal 
(e)  the samples  shall  be  accompanied  by  a  copy  of the 
summary of product characteristics; 
(f)  no samples of medicinal products conuining psvcho-
tropic or narcotic substances  within  the  meani.ng  of 
international conventions may be:  supplied.  · 
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